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Abstract Objective: To evaluate
the feasibility of using a knowledge-
based system designed to automati-
cally titrate pressure support (PS) to
maintain the patient in a “respiratory
comfort zone” during noninvasive
ventilation (NIV) in patients with
acute respiratory failure. Design
and setting: Prospective crossover
interventional study in an intensive
care unit of a university hospital.
Patients: Twenty patients. Interven-
tions: After initial NIV setting and
startup in conventional PS by the chest
physiotherapist NIV was continued
for 45 min with the automated PS
activated. Measurements and results:
During automated PS minute-volume
was maintained constant while res-
piratory rate decreased significantly
from its pre-NIV value (20 ± 3
vs. 25 ± 3 bpm). There was a trend
towards a progressive lowering of dys-
pnea. In hypercapnic patients PaCO2
decreased significantly from 61 ± 9
to 51 ± 2 mmHg, and pH increased
significantly from 7.31 ± 0.05 to
7.35 ± 0.03. Automated PS was well
tolerated. Two system malfunctions
occurred prompting physiotherapist
intervention. Conclusions: The
results of this feasibility study suggest
that the system can be used during
NIV in patients with acute respiratory
failure. Further studies should now
determine whether it can improve
patient-ventilator interaction and
reduce caregiver workload.
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Introduction
Noninvasive ventilation (NIV) in pressure support mode
(PS) has become a standard of care in both hypercapnic
and nonhypercapnic acute respiratory failure [1, 2, 3].
Optimization of patient-ventilator interaction is a critical
factor determining the success of the technique in avoiding
endotracheal intubation [4, 5]. Several key elements have
been shown to play an important part in patient-ventilator
interaction: discomfort due to either insufficient or exces-
sive levels of PS [6], worsening dynamic hyperinflation
in obstructive patients due to excessive PS, and resultant
increase in the number of ineffective inspiratory attempts
and work of breathing [7, 8]. Furthermore, in acutely
decompensated patients this multitasking endeavor carries
the risk of both error and suboptimal performance [9, 10].
Recently a closed-loop knowledge-based system
implemented in an ICU ventilator designed to automat-
ically adjust the level of PS in intubated patients has
demonstrated its ability to improve patient-ventilator
interaction [11], assist in the management of weaning [12,
13], and shorten its duration [14]. Theoretically the
automatic titration of PS could for the same reasons
improve patient-ventilator interaction also during NIV and
possibly reduce the clinician’s workload. The present pilot
study tested the feasibility of applying the closed-loop
system during NIV in patients with acute respiratory
failure.
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Patients and methods
Patients
All patients admitted to the ICU of two university hospi-
tals (University Hospital, Geneva, Switzerland, and St-Luc
University Hospital, Brussels, Belgium) for acute respi-
ratory failure and in whom NIV was prescribed were in-
cluded. Patients were included if they had been treated in
the hospital for ≤ 4 h or less and had received at most two
NIV applications. Exclusion criteria were the presence of
pneumothorax, severe respiratory failure or hemodynamic
instability with high probability of imminent intubation,
impaired consciousness or absence of patient cooperation,
and presence of facial lesions precluding the use of NIV.
The study included 20 patients (11 men, 9 women; age
66.5 ± 12.1 years; body mass index 29.7 ± 9.3). Thirteen
presented with hypercapnic respiratory failure (eight de-
compensated chronic obstructive pulmonary disease, two
postoperative, one each chronic restrictive disease, pan-
creatitis, and acute heart failure) and seven with nonhy-
percapnic respiratory failure (five pneumonia, one sepsis,
one following hepatic transplantation). The patients had
been treated inhospital for a mean of 17 ± 6 h. Fourteen of
the 20 patients had received NIV (mean 1.4 ± 0.5 applica-
tions). The protocol was accepted by the Ethics Committee
of our institution. Informed consent was obtained from all
patients.
Methods
Patients were ventilated with an Evita XL ICU ventilator
(Drägerwerk, Lübeck, Germany) in which the evaluated
system is embedded and accessible via a touch-screen
menu under the commercial name of SmartCare. The
knowledge base used to develop this system comes mainly
from the scientific literature and from a group of inten-
sivists, physiologists, and scientists. A detailed description
of the system has been published elsewhere [12, 15].
Briefly, the system adapts the level of PS to continuously
monitored patient data, pursuing the goal of keeping the
patient within a respiratory “comfort” zone. The latter is
defined as a respiratory rate varying between 15–30 bpm
(upper limit 34 in patients with neurological disease), tidal
volume above a minimum threshold (300 ml, reduced to
250 ml if patient body weight is < 55 kg), and end-tidal
expiratory CO2 below 55 mmHg (65 mmHg in patients
with chronic obstructive pulmonary disease). To reach
these targets the level of PS is periodically adapted by the
system in steps of 2–4 cmH2O. The period between eval-
uations leading to a decision by the system as to whether
to change the level of PS is 2 min in the absence of any
change in PS, and 5 min if such a change has been made.
The first evaluation after the system has been activated
occurs after 5 min. Thereafter several additional rules
allow the system to manage transient instabilities, suction-
ing, or hazardous situations. In addition, the system has
a second set of rules centered on the goal of automatically
attempting to reduce the level of PS down to a minimal
level. Briefly, these rules consist of a reduction in the level
of PS if a patient has remained in the “comfort zone” for
a given period, the duration of which depends on the level
of PS. Once the minimal level of PS is attained, if the
patient remains in the “comfort zone” at that level, an eval-
uation period at that minimal level of PS is initiated by the
system (equivalent to a spontaneous breathing trial) which
if successful leads to an on-screen message recommending
extubation. However, this set of rules centered on weaning
was inactivated for the present trial as the objective was
only to test the feasibility of automatic adjusting PS and
not to attempt weaning from mechanical ventilation.
Therefore only the automatic titration of PS aiming to
maintain the patient in the “comfort zone” was activated.
Criteria for initiating NIV followed our usual practice
guidelines which are based on published studies [16, 17]
and require that at least two of the following be present:
worsening dyspnea over the last 10 days in cases of chronic
respiratory failure; respiratory rate above 25/min, arterial
pH below 7. 35, PaCO2 higher than 50 mmHg (6.6 kPa),
and PaO2 lower than 50 mmHg (6.6 kPa) determined from
arterial blood gas measurements.
All NIV trials were performed by one of the chest
physiotherapists involved in the study (A.B. in Geneva,
J.R. in Brussels), both highly experienced in the technique
and with the SmartCare system. NIV was initially applied
with an oronasal mask (adult face mask, Vygon Schweiz,
Liebefeld-Bern, Switzerland) in PS mode, the initial
settings being: 15 cmH2O PS, fast pressurization slope
(0.1 s), and no positive end-expiratory pressure (PEEP).
In all patients airways were humidified with a heat and
moisture exchanger (BB100, Pall, East Hills, N.Y. USA).
PS was then titrated according to our usual practice guide-
lines: the level of PS was adjusted to obtain an expired tidal
volume of 8 ml/kg and a respiratory rate less than 30/min,
with a minimal leak at the mask. In obstructive patients,
PEEP was titrated upwards until the number of ineffective
inspiratory attempts either disappeared or decreased to
below 6/min. In nonobstructive patients a PEEP between
3–6 cmH2O was used, the level titrated to maintain
pulsoxymetry-determined arterial O2 saturation (SpO2) at
or above 90%. This initial startup period was necessary for
several reasons. First, SmartCare requires manual setting
of the initial level of PS before it can be activated. Second,
given the preliminary nature of the study we wanted to
ensure sure that the patients’ initial adaptation to NIV was
adequate, for which the initial 5-min evaluation period
built in the system might not have been appropriate. Third,
PEEP in patients with chronic obstructive pulmonary
disease is often important to decrease the number of
ineffective inspiratory efforts, and its titration is not part
of the system’s algorithm. Once these targets had been
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Table 1 Main respiratory parameters and ventilator settings
[NA not available, NIV startup end of the 10-min initial
startup/adaptation NIV period before SC was activated, pre-
NIV before initiation of noninvasive ventilation, RR respira-
tory rate, SC SmartCare driven NIV after 10, 20, 30 and 45
min respectively, VAS visual analog scale (0 = no dyspnea,
10 = severe dyspnea), VTe expired tidal volume, VE minute
volume]
Pre-NIV NIV startup SC 10 SC 20 SC 30 SC 45
RR (breaths/min) 25 ± 3 22 ± 5 21 ± 5 21 ± 4 20 ± 3* 21 ± 3
VTe (ml) NA 686 ± 190 700 ± 200 670 ± 205 735 ± 237 717 ± 205
VE (l/min) NA 13.1 ± 3.6 12.5 ± 3.3 2.4 ± 3.2 12.8 ± 3.1 13.4 ± 2.8
Dyspnea 3.2 ± 1.7 2.8 ± 1.6 2.2 ± 1.1 2.2 ± 1.1 2.1 ± 0.9 2.0 ± 1.0
(VAS points)
Pressure support NA 17 ± 3 18 ± 4 16 ± 5 17 ± 5 16 ± 5
(cmH2O)
FIO2 0.32 ± 0.02 0.28 ± 0.05 0.29 ± 0.04 0.31 ± 0.03 0.28 ± 0.04 0.28 ± 0.04
PEEP (cmH2O) NA 5 ± 0.3 5 ± 0.4 5 ± 0.3 5 ± 0.3 5 ± 0.4
Leaksa NA 23 ± 5 22 ± 4 24 ± 6 20 ± 4 21 ± 3
∗ p < 0.05 vs. pre-NIV (analysis of variance)
a Reported by the ventilator, expressed as a proportion of VE: (VTi−VTe)/VTi, where VTe = expired tidal volume and VTi = inspired tidal
volume
attained, the initial startup period was considered over,
and the SmartCare system was activated and NIV pursued
for 45 min. The therapist remained at the bedside during
the entire procedure and manually adjusted the level of
PS, PEEP, FIO2, or mask fitting in the case of obvious
patient-ventilator asynchrony or discomfort, if SpO2
decreased to less than 88%, or respiratory rate increased
to above 30 for more than 3 min. All changes performed
were then recorded automatically in the machine’s log.
After 45 min NIV was discontinued. If patients required
further NIV sessions, the technique was applied without
the SmartCare system. The following parameters were
recorded before the start of NIV (pre-NIV), at the end
of the startup/adaptation period (NIV startup), and after
10, 20, 30, and 45 min of NIV using SmartCare (SC 10,
SC 20, SC 30, SC 45): respiratory rate, expired tidal vol-
ume, minute volume, leaks at the mask [(VTi – VTe)/VTi,
where VTe = expired tidal volume and VTi = inspired tidal
volume), arterial blood gases (not performed at 10 and
30 min), SpO2 and end-tidal expired CO2 measured at
the mask (both continuously recorded), dyspnea (visual
analog scale), heart rate, and arterial blood pressure.
Statistics
All results are expressed as mean ( ± SD). The six time-
points were compared by analysis of variance (SigmaS-
tat 2.0, SPSS Science), with significance between the time
points being determined by Fisher’s protected least signif-
icance test. A p value of less than 0.05 was considered sta-
tistically significant.
Results
The end of the startup/adaptation period with conventional
PS was achieved after 10 ± 4 min. Ventilator settings at
Fig. 1 Individual variations in the level of pressure support during
SmartCare-driven NIV. NIV startup End of the 10-min initial
startup/adaptation NIV period before SC was activated; SC 10,
SC 20, SC 30, SC 45 measurements performed after 10, 20, 30, and
45 min of SmartCare driven NIV, respectively
the end of that period were: level of PS 17.2 ± 3 cmH2O,
PEEP 5 ± 0.7 cmH2O, and FIO2 0.29 ± 0.04. The main
respiratory parameters and course of ventilator settings are
summarized in Table 1. During the 45 min of SmartCare
NIV minute volume and tidal volume were stable while
respiratory rate slowly declined, reaching statistical signif-
icance compared to its pre-NIV value after 30 min. Con-
comitantly there was a trend towards a decrease in dys-
pnea. The PS level was maintained fairly constant by the
system. The individual variations in PS as set by the system
are shown in Fig. 1. During the 45-min period there were
no changes in PS in six patients, one automatic change in
six other patients, and more than one automatic change in
eight (two in six patients and three changes in two).
Table 2 summarizes the course of arterial blood gases
and hemodynamics. There was a trend towards a decrease
in PaCO2 in the group of patients as a whole, which was
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Table 2 Arterial blood gases and hemodynamics (ETCO2 end-tidal
CO2, HR heart rate, MAP mean arterial pressure, NA not available,
NIV startup end of the 10-min initial startup/adaptation NIV pe-
riod before SC was activated, PaO2 arterial partial pressure of O2,
PaO2/FIO2 ratio of arterial partial pressure of O2 to inspired O2 frac-
tion, PaCO2 arterial partial pressure of CO2)
Pre-NIV NIV startup SC 10 SC 20 SC 30 SC 45
pH
All 7.37 ± 0.06 7.38 ± 0.06 NA 7.38 ± 0.05 NA 7.39 ± 0.04
Acidotica 7.31 ± 0.05 7.32 ± 0.02 NA 7.34 ± 0.03 NA 7.35 ± 0.03*
PaCO2 (mmHg)
All 50 ± 11 44 ± 8 NA 44 ± 9 NA 43 ± 6
Hypercapnicb 61 ± 9 57 ± 4 NA 54 ± 3* NA 51 ± 2*
PaO2 (mmHg) 73 ± 15 75 ± 11 NA 75 ± 13 NA 77 ± 14
PaO2/FIO2 228 ± 28 267 ± 21 NA 241 ± 23 NA 275 ± 18
ETCO2 (mmHg)
All NA 29 ± 7 30 ± 8 29 ± 6 29 ± 7 30 ± 7
Hypercapnicb NA 33 ± 7 35 ± 6 34 ± 6 34 ± 5 33 ± 6
HR (bpm) 88 ± 16 87 ± 13 84 ± 16 83 ± 19 85 ± 12 85 ± 13
MAP (mmHg) 82 ± 15 81 ± 10 80 ± 11 80 ± 10 82 ± 10 81 ± 10
∗ p < 0.05 vs. pre-NIV (analysis of variance)
a Defined as initial pH < 7.35
b Defined as a PaCO2 ≥ 45 mmHg
significant in the hypercapnic patients after 20 min of
SmartCare NIV. This was accompanied by a significant
increase in pH in patients who were initially acidotic.
Likewise, in the two patients whose initial pH was higher
than 7.45, pH decreased from 7.52 to 7.45 and from 7.45
to 7.42, respectively.
Two problems were encountered that were directly
linked to the system. In one patient the end-tidal CO2
(ETCO2) sensor malfunctioned, exhibiting values in turn
above and below the threshold, which led to erratic PS
settings and poor patient tolerance. The problem subsided
after the sensor was changed. In another patient the
respiratory rate recorded by the system was higher than
that of the patient, leading to an unnecessary increase in
the PS level. The problem was solved by rebooting the
system. No other outside intervention from the therapist
was required other than improving mask fitting. In no
patient was the 45-min NIV trial discontinued because of
intolerance or malfunction.
Discussion
The results of this study show that it is possible to per-
form NIV using a closed-loop knowledge-based system
designed to automatically titrate the level of PS with the
goal of optimizing weaning from mechanical ventilation
in intubated patients. Before discussing the implications
of these results, let us first examine the limitations of this
study.
First, this was a feasibility study designed to test
whether the knowledge-based system could be applied to
NIV during a single 45-min trial. Therefore no conclusion
can be drawn as to how it compares to NIV conducted by
an ICU nurse or respiratory therapist nor about any impact
it might have on patient outcome. The duration of NIV ap-
plication was, however, in line with that reported in other
studies [18, 19, 20]. Second, the system’s algorithms are
designed to combine automatic PS setting and a weaning
strategy in intubated patients. Therefore its application to
NIV would require the development of rules and settings
tailored to the specific aspects of that technique and their
clinical validation. Third, the therapists conducting NIV
were part of the investigating team, which could introduce
bias in the results. However, for safety reasons it was
deemed mandatory that the SmartCare NIV trial be su-
pervised by a person highly trained and experienced with
the system. Likewise, a rapid initial startup/adaptation
NIV phase by an experienced therapist was important
so that the system could be applied in patients who
were not entirely stabilized after a prolonged period on
NIV. Furthermore, a written record was required for all
changes made in ventilator settings during the 45-min
SmartCare NIV trial, and no intervention other than the
two required by system problems were needed. That said,
mask adjustments were performed by the therapist, and
this certainly contributed to the fairly low level of leaks
documented. Severe leaks might interfere with the systems
algorithm, and the precise impact of leaks on its overall
performance should be explored if its application to NIV
were to be pursued. Finally, the patient group was small
and heterogeneous. Nonetheless, the diagnostic categories
were representative of the usual cause for which NIV is
required in the acute setting [2].
The main message of this study is that it is possible to
conduct NIV using an algorithm designed to automatically
titrate the level of PS to maintain the patient within
a predefined respiratory “comfort zone.” The system
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proved capable of maintaining an adequate minute-
volume while the patients’ respiratory rate declined,
a response which has been documented in patients with
both hypercapnic and nonhypercapnic respiratory failure
undergoing conventional NIV. During the 45-min trial
patients were maintained within the limits defining the
“comfort zone.” These results are encouraging and are in
line with those of two previous studies showing that the
system can maintain intubated patients within these limits
during periods ranging from 24 h [11] to 12 days [13].
However, the two system malfunctions encountered, both
requiring the therapist’s intervention, should be kept
in mind. Indeed, while quickly solved, these problems
were a source of patient-ventilator asynchrony, precisely
what one might hope to alleviate with automated systems
such as SmartCare. These problems underline the need
for further development of this product if it should be
considered for NIV use.
The reduction in PaCO2 documented in the hypercap-
nic patients was also in line with results from other studies
in comparable patients [18, 19]. The level of PS measured
at the various time points was close to that reached at the
end of the startup/adaptation period and is within the range
usually reported in acute NIV [18, 21]. Interestingly, the
ETCO2 showed little change during the study and exhib-
ited a large gap compared to PaCO2. This finding is not
very surprising given the presence of leaks that are ex-
pected to alter ETCO2 readings and underline the lack of
appeal in using ETCO2 as a monitoring tool during NIV.
If future studies confirm the feasibility of using this
system on a larger scale during NIV, it could prove use-
ful in the management of acutely decompensated patients
for several reasons. First, by avoiding insufficient and ex-
cessive levels of PS, both a source of major discomfort [6],
patient tolerance could be improved, which is a key factor
in the success of the technique in avoiding intubation [4, 5].
Second, in obstructive patients excessive levels of PS can
lead to worsening dynamic hyperinflation, in turn result-
ing in an increase in the number of ineffective inspira-
tory attempts [8]. Avoiding such high levels could there-
fore avoid unnecessary increases in the work of breathing
associated with this condition [7]. Finally, applying NIV
in the acute setting implies that the clinician’s attention
be divided between the proper setting of ventilator param-
eters, minimizing leaks at the mask-patient interface, and
continuously monitoring vital parameters, all the while at-
tempting to comfort an often agitated and anxious patient.
Such multitasking performed in acute and stressful con-
ditions is a well-recognized contributing factor to the oc-
currence of incidents [9, 10]. Automation of some of the
tasks associated with NIV could help reduce some of these
risks [10], provided that the algorithms used are robust and
safe enough.
In conclusion, the present study demonstrates the feasi-
bility of using a commercially available knowledge-based
system to automatically titrate the level of PS during NIV
in patients with acute respiratory failure. Although clearly
not a validation of the concept of using such a system in
routine clinical practice at this stage, these results suggest
that future studies should now be conducted, initially fo-
cusing on: (a) the design and validation of specific rules
for the use of SmartCare during NIV and (b) whether the
system compares favorably to conventionally titrated PS,
and proves beneficial in terms of caregiver workload and
improved patient tolerance.
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